Marinus Pharmaceuticals Inc (STU:61Y)
€ 0.292 0.076 (35.19%) Market Cap: 19.67 Mil Enterprise Value: 32.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Marinus Pharmaceuticals, Inc. - Special Call Transcript

Sep 14, 2020 / 08:30PM GMT
Release Date Price: €7.2 (+9.09%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Marinus Pharmaceuticals conference call to discuss the results of the company's Phase III CDKL5 deficiency disorder trial. My name is Chantal, and I will be your operator for today's call. (Operator Instructions) Please be advised that this call is being recorded at Marinus' request.

Now I would like to introduce our host for today's call, Sasha Damouni Ellis, Vice President, Investor Relations and Corporate Communications. Please go ahead.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of IR & Corporate Communication

Thank you, operator, and thank you all joining us today to discuss the results of our Phase III Marigold Study. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Edward Smith, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements made today could be deemed forward-looking under the securities laws. These forward-looking statements are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot